Protocol ATI001-102 Expansion Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects with Recurrent or Progressive Glioblastoma
Brief description of study
If you have been diagnosed with a malignant brain tumor that has grown despite standard treatments, you may qualify for this study. The main goal of this Phase I study is to evaluate the safety, tolerability, and effects of the therapy of Ad-RTS-hIL-12 and veledimex in subjects with brain tumors that are unresponsive to standard of care.
Clinical Study Identifier: s18-00164
ClinicalTrials.gov Identifier: NCTs18-00164
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
